How do GLP-1 and GIP receptor agonists relate to Retatrutide?
Retatrutide, also called LY3437943, was developed as an agonist at GIP, GLP-1 and glucagon receptors. Its discovery paper reports receptor experiments alongside animal work and early human observations. These evidence types should be read separately: receptor activity is not the same measurement as a clinical outcome.
Sources: LY3437943: from discovery to clinical proof of concept
What can a human trial add?
Urva and colleagues studied LY3437943 in a phase 1b trial involving people with type 2 diabetes. Such work examines a defined population, trial material and supervised study conditions. It does not establish the effects of an unrelated catalogue product.
Sources: LY3437943 in people with type 2 diabetes: a phase 1b trial
What does metabolic health mean in a research paper?
Metabolic health is a broad topic, not a single trial endpoint. Check whether a study measured glucose control, body weight, body composition, liver fat or another outcome. Our Retatrutide guide separates these measurements and links to the corresponding publications.
Terms such as obesity treatment, weight loss and peptide therapy can describe clinical questions. They do not make laboratory research materials medicines or establish their suitability for personal use. This library provides research context, not treatment recommendations.
Sources and further reading
This guide summarises selected sources. Original publications contain the full methods, results and disclosures; the selection is not a systematic review.
- LY3437943: from discovery to clinical proof of concept (external)
Coskun et al. Cell Metabolism (2022). Receptor, preclinical and early clinical research.
- LY3437943 in people with type 2 diabetes: a phase 1b trial (external)
Urva et al. The Lancet (2022). Randomised human study.
Continue exploring
Published study records · Quality documentation · Research peptide catalogue